BS051

BS051 is a preclinical mRNA-based nucleic acid therapy being developed by Wuhan Binhui Biotechnology (also known as Binhui Bioworks). It is designed for the treatment of solid tumors, utilizing mRNA technology to deliver genetic instructions for the expression of therapeutic proteins within the tumor microenvironment. This candidate is part of Binhui's strategic expansion into the nucleic acid drug space, complementing its established expertise in oncolytic virus platforms. While the specific target protein encoded by BS051 has not been publicly disclosed, the therapy is intended to modulate the immune system or directly inhibit tumor progression to achieve anti-tumor effects. It is currently in the preclinical stage of development.